BACKGROUND
A set of common cancer-related and treatment-related symptoms has
been proposed for quality-of-care assessment and clinical research. Using
data from a large, multicenter, prospective study, we assessed effects of
disease site and stage on the percentages of patients rating these proposed
symptoms as moderate to severe.
METHODS
The severity of 13 symptoms proposed to represent
“core” oncology symptoms was rated by 3106 ambulatory
patients with cancer of the breast, prostate, colon/rectum, or lung,
regardless of disease stage or phase of care; 2801 patients (90%)
repeated the assessment 4–5 weeks later.
RESULTS
At the initial assessment, approximately one third of the patients
reported ≥3 symptoms in the moderate-to-severe range; 11 of the 13
symptoms were rated as moderate to severe by at least 10% of all
patients and 6 by at least 20% of those in active treatment.
Fatigue/tiredness was the most-severe symptom, followed by disturbed sleep,
pain, dry mouth, and numbness/tingling. More lung cancer patients and
patients in active treatment reported moderate-to-severe symptoms.
Percentages of symptomatic patients increased by disease stage,
less-adequate response to therapy, and declining performance status.
Percentages of patients reporting moderate-to-severe symptoms were stable
across both assessments.
CONCLUSIONS
These results support a core set of moderate-to-severe symptoms
common across outpatients with solid tumors that can guide consideration of
progression-free survival as a trial outcome and that should be considered
in clinical care and in assessments of quality of care and treatment
benefit.
Release of immature white blood cells into the circulation may also contribute to a failure to clear infection and an increased propensity to organ failure. Concomitantly, profound changes occur within the bone marrow, which include the increased release of erythroid and myeloid progenitors into the circulation, a decrease in progenitor cell growth within the bone marrow, and an impaired growth of the bone marrow stroma. Erythropoietin levels are preserved following trauma, implying that the persistent anemia of injury is related to the failure of the bone marrow to respond to erythropoietin.
The purpose of this study was to identify independent predictors of clinically significant fatigue based upon a multidimensional model. A total of 180 cancer patients completed the Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy-Fatigue (FACT-F), Memorial Symptom Assessment Scale Short Form (MSAS-SF), and the Zung Self-Rating Depression Scale (SDS). Additional data included Karnofsky Performance Status (KPS) score, laboratory tests, and demographic information. The BFI usual fatigue severity > or =3/10 was defined as clinically significant fatigue. Possible independent variables were identified from a biopsychosocial model of fatigue. Fisher's exact test was used to univariately assess the association of each variable with clinically significant fatigue. Multiple logistic regression analyses were used to identify independent predictors of fatigue within each dimension, and then across dimensions. Fatigue was present in 113 (62%) patients, and 80 (44.4%) patients had usual fatigue > or =3/10. The unidimensional independent predictors were use of analgesics (situation dimension); hemoglobin and serum sodium (biomedical dimension); feeling drowsy, dyspnea, pain and lack of appetite (physical symptom dimension); and feeling sad and feeling irritable (psychological symptom dimension). In a multidimensional model, dyspnea, pain, lack of appetite, feeling drowsy, feeling sad, and feeling irritable predicted fatigue independently with good calibration (Hosmer Lemeshow Chi Square=5.73, P=0.68) and discrimination (area under the receiver operating characteristic curve=0.88). Physical and psychological symptoms predict fatigue independently in the multidimensional model, and superseded laboratory data. These findings support a symptom-oriented approach to assessment of cancer-related fatigue.
A B S T R A C T PurposePain is prevalent among patients with cancer, yet pain management patterns in outpatient oncology are poorly understood.
Patients and MethodsA total of 3,123 ambulatory patients with invasive cancer of the breast, prostate, colon/rectum, or lung were enrolled onto this prospective study regardless of phase of care or stage of disease. At initial assessment and 4 to 5 weeks later, patients completed a 25-item measure of pain, functional interference, and other symptoms. Providers recorded analgesic prescribing. The pain management index was calculated to assess treatment adequacy.
ResultsOf the 3,023 patients we identified to be at risk for pain, 2,026 (67%) reported having pain or requiring analgesics at initial assessment; of these 2,026 patients, 670 (33%) were receiving inadequate analgesic prescribing. We found no difference in treatment adequacy between the initial and follow-up visits. Multivariable analysis revealed that the odds of a non-Hispanic white patient having inadequate pain treatment were approximately half those of a minority patient after adjusting for other explanatory variables (odds ratio, 0.51; 95% CI, 0.37 to 0.70; P ϭ .002). Other significant predictors of inadequate pain treatment were having a good performance status, being treated at a minority treatment site, and having nonadvanced disease without concurrent treatment.
ConclusionMost outpatients with common solid tumors must confront issues related to pain and the use of analgesics. There is significant disparity in pain treatment adequacy, with the odds of undertreatment twice as high for minority patients. These findings persist over 1 month of follow-up, highlighting the complexity of these problems.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.